Bristol-Myers Squibb Company (BMS) and Pfizer have announced that eight abstracts have been accepted for presentation at the American College of Cardiology (ACC) 66th annual scientific session, taking place March 17-19 in Washington, D.C. In addition to post-hoc analyses from the pivotal phase 3 ARISTOTLE (Apixaban for Reduction In STroke and Other ThromboemboLic Events in Atrial Fibrillation) trial, the Bristol-Myers Squibb and Pfizer Alliance will present real-world data analyses that illustrate the Alliance’s ongoing commitment to understanding the use of direct oral anticoagulants, including Eliquis (apixaban), in routine clinical practice. This real-world research, part of the global ACROPOLIS (Apixaban ExperienCe Through Real-WOrld POpuLatIon Studies) programme, aims to complement findings from clinical trials and contribute to the growing body of knowledge around anticoagulation.
In a late-breaking clinical trials session, the Alliance will highlight a post-hoc analysis from the ARISTOTLE trial, titled ARISTOTLE: digoxin and mortality in patients with atrial fibrillation with and without heart failure: does serum digoxin concentration matter? Results of the analysis will be presented on March 19 at 11:00 a.m. Eastern Daylight Time.
“During ACC, the Bristol-Myers Squibb and Pfizer Alliance will share several analyses that delve deeper into the robust data generated from the ARISTOTLE study,” said Christoph Koenen, MD, MBA, vice president, development lead, Eliquis, Bristol-Myers Squibb. “Through continued analyses and support of the ARISTOTLE trial, we can examine topics such as outcomes for patients with different comorbidities and the potential treatment effects of interacting drugs, which expands our scientific understanding.”
“As physicians evaluate options for reducing stroke risk in patients with non-valvular atrial fibrillation, they often face questions about the effectiveness and safety of therapies in day-to-day practice,” said Rory O’Connor, MD, chief medical officer, Pfizer Innovative Health. “Real-world data analyses allow us to explore the usage of Eliquis and anticoagulants across various geographies and subgroups of patients. Alongside clinical data, the real-world data analyses we are presenting during ACC have the potential to help healthcare providers make more informed decisions along with their patients.”